The Traderszone Network

Published in TZ Latest News 12 May, 2014 by The TZ Newswire Staff

Pfizer presses AstraZeneca case as CEO faces UK grilling

U.S. drugmaker Pfizer (PFE.N) pressed the scientific case for its controversial plan to acquire AstraZeneca (AZN.L) on Monday as its chief executive prepared for a grilling from British lawmakers. In the latest phase of Pfizer’s campaign to counter critics of its proposed $106 billion deal, research head Mikael Dolsten said he had been through five different mergers and acquisitions and denied such big transactions disrupted drug research.

read more